The trial will evaluate the safety and efficacy of the Novavax’ NVX-CoV2373 vaccine candidate in approximately 10,000 UK participants.
List view / Grid view
Filter the results
A Phase III clinical trial to evaluate J&J's COVID-19 vaccine in multiple countries has enrolled its first patients.
A contract for 300 doses of the investigational COVID-19 vaccine candidate has been signed by the European Commission (EC).
An Emergency Use Authorization (EUA) request for the use of RLF-100™ (aviptadil) in critical COVID-19 patients was submitted to the US FDA.
Researchers who designed a transmission model for COVID-19 demonstrated that attempting to establish herd immunity against COVID-19 would be too challenging.
Operation Warp Speed and the NIH are funding the expansion of two trials evaluating the efficacy of convalescent plasma therapy in hospitalised COVID-19 patients.
The FDA has given the green light to an IND and further Phase I clinical trial of Ampio Pharmaceuticals' Ampion as an inhaled COVID-19 therapy.
A Phase III trial concluded that avelumab is an effective maintenance therapy for patients with advanced or metastatic urothelial carcinoma, whose disease had not progressed after chemotherapy.
The implanted biomaterial drug delivery system releases methylprednisolone and reduces inflammation, promoting central nervous system (CNS) repair.
Prashant Khadayate, Pharma Analyst at GlobalData, explains what the current state of the COVID-19 pandemic is in India and what vaccine options are currently under development/testing.
A study of baricitinib in combination with remdesivir has met its primary endpoint in COVID-19 patients, by reducing time to recovery in comparison with only remdesivir.
REGN-COV2 will be evaluated alongside standard-of-care in a Phase III study as part of the COVID-19 RECOVERY trial.
Vaxart's application for a Phase I clinical trial to evaluate its oral COVID-19 vaccine candidate has been cleared by the FDA.
The adaptive Phase III trials will assess whether various types and doses of blood thinners can prevent COVID-19 patients forming potentially fatal blood clots.
The data suggests disease deterioration was halved in the six Amyotrophic Lateral Sclerosis (ALS) patients treated with IPL344 over eight months.